Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02477696 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02477696 · ClinicalTrials.gov record · last posted 2026-08-26

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Name: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — clinical trial record (NCT02477696)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 3

SponsorAcerta Pharma BV

Started2015-07-28

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.

Amendment record 42 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 42 times since 2015-06-22; most recent amendment 2026-05-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2017-12-14

Status change Recruiting→Active, Not Recruitingv19

2015-06-29

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT02477696
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia
Enrollment	533 participants
Start Date	2015-07-28
Primary Completion	2020-09-15 (estimated)
Study Completion	2028-01-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-26